Zylexis
Active substance
ATC code
Species
Horses, from 10 months of age.
Indications
Zylexis for horses acts by stimulation of the non-specific immune mechanisms and is of potential clinical value in the reduction of clinical signs of stress/crowding associated equine respiratory disease.
In a field study, reduction of clinical signs (defined as the first time-point at which significant differences were evidenced between groups) was shown on day 5 after administration of the full treatment schedule and lasted less than a week. This is a Limited Marketing Authorisation. A full set of supporting efficacy data is not available for this product.
Dose to be administered and administration route
Aseptically reconstitute the lyophilisate with the solvent provided. Shake well before use. The entire contents of the reconstituted vial should be administered intramuscularly as a single dose, irrespective of the body weight of the animal.
Dosage regimen
Three injections of a single dose for each animal are recommended.
The first two injections are administered with a 48-hours interval (day 0 and day 2) and the third injection should be administered on day 9.
Adverse reactions
Hyperthermia associated with general malaise and musculoskeletal signs (stiffness, abnormal posture, tense muscle) have been observed very rarely in spontaneous reports.
Hypersensitivity reactions (i.e. circulatory shock, tachycardia, abdominal pain, convulsion) may occur very rarely. Such reactions may evolve to a more severe condition (anaphylaxis), which may be life-threatening.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
